Basem Goueli MD/PhD/MBA

CancerClarity

We are in our early stages in the development of CancerClarity, which is in the clinical trial, pharmaceutical consulting, cancer center consulting, and clinical treatment forums.  We are presently in stealth mode.

CEO and Founder

CancerLight

We are in the early stages of developing CancerLight, a company in the patient education space.  We are presently in stealth mode.

Catholic Health

Medical director of hematology/medical oncology for Catholic Health System.

Medical Director of Hematology/Medical Oncology

Great Lakes Cancer Care

Director of Hematology and Medical Oncology

University at Buffalo

Associate Chief of Hematology/Medical Oncology

Covenant Health/Thompson Oncology Group

St. Luke's Reginoal Cancer Center

Director

I have directed three independent cancer institutes, collectively representing 17 hospitals and 12 cancer centers.  I am a hematologist and medical oncologist who has been the institutional principal investigator on nearly 100 clinical trials involving breast cancer, myeloma, prostate cancer, lung cancer, melanoma, ovarian cancer, head and neck cancer, myelodysplastic syndrome, CLL, DLBCL, esophageal cancer, etc.  I was on three papers published in The New England Journal of Medicine (prostate cancer, chronic neutrophilic leukemia, lung cancer) and two in Lancet (Shingles vaccine and head and neck cancer).  I am board certified in hematology, medical oncology, internal medicine, and artificial intelligence in medicine.


As depicted in my profile, my training background includes:
MD:  Mayo Clinic
PhD in biochemistry:  Mayo Clinic
MBA:  University of North Carolina, Chapel Hill
Internal Medicine Residency:  George Washington University Hospital with 4 months at the NIH
Hematology/Oncology Clinical Fellowship:  Stanford
Biochemistry Post-Doctoral Fellowship:  Stanford
MIT Xpro Course Certificate:  Designing Artificial Intelligence Products 
MIT Xpro: Course Certificate:  Robotics Essentials 
MIT Xpro: Course Certificate:  Drug and Medical Device Development 
MIT Professional Education Course Certificate:  Applied Data Science Bootcamp

I resisted the trend towards subspecialization in my career as I feel ideation often happens at the level of the forest, not the trees.  Many of the greatest future innovations will be at the interface of various disciplines. 

My area of clinical expertise is precision medicine, and my ability to treat patients in all hematology/medical oncology disciplines uniquely positions me to sequence molecular-based therapies in the context of conventional therapy and clinical trials.

I am the CEO and Founder of three companies:  CancerClarity, CancerLight, and Revolution Cancer Medical Care PLLC.  We are early in our development as we hope to disrupt the clinical trial, patient education, and clinical care forums.  Aside from building my two companies, I am a consulting medical director for 2 phase 1 Xbiotech clinical trials (pancreatic cancer), consult for numerous other pharmaceutical companies, and see patients full-time in the clinic as a hematologist/medical oncologist.  I recently turned down several high-visibility positions to pursue my vision.

My singular focus is to help as many people as I can in the shortest time frame possible.

Genosco

Drug discovery R & D, Target identification, Lead optimization, Small molecules, Preclinical sciences, Oncology & Inflammatory diseases.

Principal Scientist

Senior Scientist

Rutgers University

Research Professor/Biomedical Engineering

Rutgers Cancer Institute of New Jersey

●	Design and develop research plans, organize collaborative inter-disciplinary/inter-institutional teams, execute project with oversight and responsibility for data integrity/analysis, provide study completion reports on time. 
●	Provide performance assessments, manage laboratory, budgeting, accounting, make hiring, purchase and expense decisions. Research outsourcing, delegating, data collection, drafting literature and disseminating project reports in group meetings and national/international conferences
●	Technical troubleshooting, instrumentation, training support. 
●	Establish industry-academic partnership for lymphoma research activities, such as for preclinical assessment of  CD19-CAR-NK (Natural Killer), anti-TIM3, anti-LAG3 and anti-PD1 therapeutic activity (NantKwest, Tesaro), academic partnership for technology development to assess antibody (rituximab/obinutuzumab) drug activity (NIH sponsored).
●	Maintain robust library of oncology pipeline compounds.
●	Develop combinatorial regimens with targeted drugs and immunotherapeutic drugs (I/O) for hematological malignancies. Develop a biomarker portfolio for monitoring therapeutic responses.

Investigator/Laboratory Manager

Rutgers Robert Wood Johnson Medical School

●	Establish industry-academic partnership lymphoma research activities, designed and executed research plans for the following Ixazomib/Ninlaro with Takeda, Buparlisib with Novartis-Canine clinical trial, IPI-145 with Infinity pharmaceutical, AFM13 bispecific antibody/Affimed- human clinical trial, Immune checkpoint marker clinical assessment (Tesaro). 
●	Leading Investigator and project administrator for multi-institutional and interdisciplinary research activities. 
●	Mentored/supervised members research staffs, maintained large laboratory, organized staff meetings, prepare students for thesis defense, authored research project proposals, completion reports, set goals, and met deadlines on time.
●	Involved as bench scientist, designed and executed research activities, served as operational manager for flow cytometry core facility.
●	Participated and presented in group meetings, internal/external, national and international conferences.

Adjunct Faculty

Covimro Ltd.

Scientific Officer (Virtual)

Tufts Medical Center

●	Defined cancer hallmark-based transcriptomic analysis and identified MYC as a key player in the proteasomal inhibitor (Ixazomib/Ninlaro) activity in lymphoma treatment. This article was published in Cancer Research 2016.
●	Leading Investigator and project administrator of industry collaboration studies, with design and investigational experience in 25 oncology pipelines, identified lead compounds with lymphoma indications that were adapted for human and canine clinical trials. 
●	Mentored/supervised members of the Hem Onc fellowships and research staffs in a large laboratory. Negotiated and completed four research projects and produced reports for industry partners. Establish multidisciplinary and multi-institutional teams, set goals, and met deadlines on time.

Research Associate II

UMass Medical School

●	Designed and conducted lymphoma preclinical studies and acquired investigational drug candidates from Ziopharm, AstraZeneca, Takeda, and Novartis through establishing collaborative partnerships 
●	Collaborated with institutional core facilities to generate patient-derived xenograft (PDX) tumor for lymphoma research.
●	Completed a multi-institutional clinical/basic translational research, and identified fatty acid metabolism as a novel target for lymphoma therapy. 
●	Mentored/supervised research staffs, organized start-up laboratory, authored research project proposals, completion reports, set goals, and met deadlines on time.

Research Scientist

UTHSCSA

●	Established high-throughput screening facility, designed and developed RNAi-based genomic screen platform, authored and published assay validation procedures and data analytical methods.  
●	Developed markers for prognostication of metastatic properties 
●	Authored a book chapter in Methods in Molecular Biology 2012, DNA repair section.
●	Contributed to software development Ortholog finder and Pathway Distiller.
●	Provided training and supervision for rotational students and staffs. Applied bioinformatic tools such as Gene Set Enrichment Analysis, IPA, R Bioconductor, and advanced statistical methods. Won several awards for two major projects. Our laboratory received grant funding worth over $2,500,000 as a result of my studies.
●	Performed tissue culture experiments 20+ cell lines, automation of high-throughput screening, liquid handling, imaging platforms, optimized and generated large scale RNAi library, RT-PCR, in vitro transcription, high-throughput transfections were adapted and developed.

Instructor and Postdoc

University of Arkansas for Medical Sciences

Discovered a novel redox cycling-based anthracycline drug activation by thioredoxin, published in Journal of Biological Chemistry 2004 and Cancer Chemotherapy and Pharmacology 2005. 

Successfully completed 5 projects related to oncology and lung biology, generated concepts for 2 patent applications, and funded investigations. Performed molecular profiling studies in baboon and human lung disease models, published 5 papers.

PostDoc

University of Texas Health Science Center at Tyler

Same as in PostDoc at University of Arkansas for Medical Sciences.

As a scientist with extensive laboratory experience in cancer biology and substantial intellectual contributions in this field, I seek thrill in solving some of the most puzzling biology of cancer.  Areas of specialization includes clinical biomarkers, preclinical discovery, translational sciences, genomics, novel therapeutics and basic cancer research. 

Knowledge and accomplishments on following aspects. 
1) Predictive markers of radiotherapy response in cancer patients, 
2) Redox biology in doxorubicin metabolism, 
3) Systems biology, 
4) Oxygen and cancer, 
5) Targeted drugs in lymphoma therapy 
6) Various forms of immunotherapies (checkpoint, CD19-CAR-NK) in lymphoma 
7) Fatty acid metabolism to DNA synthesis in cancer
8) Developed Abacus method for deciphering biological trajectories in cancer. 
9) Resolved the biological mystery of Warburg effect (pending peer review)
10) Mapped snoRNA network in lymphoma (pending peer review)    

Follow my publications at https://scholar.google.com/citations?user=uEgRMvwAAAAJ&hl=en

taplio

The Battle

Basem Goueli MD/PhD/MBA

Ravi Dashnamoorthy

Followers

Posts

Engagements

Likes

Ready to grow your LinkedIn presence?